Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance - British Journal of Cancer
- ️Roychowdhury, Sameek
- ️Thu Dec 03 2020
References
Babina, I. S. & Turner, N. C. Advances and challenges in targeting FGFR signalling in cancer. Nat. Rev. Cancer 17, 318–332 (2017).
Ornitz, D. M. & Itoh, N. The fibroblast growth factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol. 4, 215–266 (2015).
Helsten, T., Elkin, S., Arthur, E., Tomson, B. N., Carter, J. & Kurzrock, R. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin. Cancer Res. 22, 259–267 (2016).
Imamura, T. Physiological functions and underlying mechanisms of fibroblast growth factor (FGF) family members: recent findings and implications for their pharmacological application. Biol. Pharm. Bull. 37, 1081–1089 (2014).
Qin, A., Johnson, A., Ross, J. S., Miller, V. A., Ali, S. M., Schrock, A. B. & Gadgeel, S. M. Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling. J. Thorac. Oncol. 14, 54–62 (2019).
Tiong, K. H., Mah, L. Y. & Leong, C. O. Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. Apoptosis 18, 1447–1468 (2013).
Sobhani, N., Ianza, A., D’Angelo, A., Roviello, G., Giudici, F., Bortul, M., Zanconati, F., Bottin, C. & Generali, D. Current status of fibroblast growth factor receptor-targeted therapies in breast cancer. Cells 7, 76 (2018).
Göke, F., Franzen, A., Hinz, T. K., Marek, L. A., Yoon, P., Sharma, R. et al. FGFR1 expression levels predict BGJ398 sensitivity of FGFR1-dependent head and neck squamous cell cancers. Clin. Cancer Res. 21, 4356–4364 (2015).
Göke, F., Bode, M., Franzen, A., Kirsten, R., Goltz, D., Göke, A. et al. Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck. Mod. Pathol. 26, 1298–1306 (2013).
Loriot, Y., Necchi, A., Park, S. H., Garcia-Donas, J., Huddart, R., Burgess, E. et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 381, 338–348 (2019).
Abou-Alfa, G. K., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21, 671–684 (2020).
Krook, M. A., Silverman, I. M., Murugesan, K., Ernst, G., Reeser, J., Wing, M. et al. Pan-cancer analysis of FGFR1-3 genomic alterations to reveal a complex molecular landscape. J. Clin. Oncol. 38, 3620 (2020).
Forbes, S. A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H. et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43, D805–D811 (2015).
Lew, E. D., Furdui, C. M., Anderson, K. S. & Schlessinger, J. The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Sci. Signal. 2, ra6 (2009).
Hart, K. C., Robertson, S. C., Kanemitsu, M. Y., Meyer, A. N., Tynan, J. A. & Donoghue, D. J. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 19, 3309–3320 (2000).
AACR Project GENIE. Powering precision medicine through an international consortium. Cancer Discov. 7, 818–831 (2017).
André, F. & Cortés, J. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res. Treat. 150, 1–8 (2015).
Gallo, L. H., Nelson, K. N., Meyer, A. N. & Donoghue, D. J. Functions of fibroblast growth factor receptors in cancer defined by novel translocations and mutations. Cytokine Growth Factor Rev. 26, 425–449 (2015).
Dutt, A., Salvesen, H. B., Chen, T. H., Ramos, A. H., Onofrio, R. C., Hatton, C. et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl Acad. Sci. USA 105, 8713–8717 (2008).
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153–158 (2007).
Hernández, S., López-Knowles, E., Lloreta, J., Kogevinas, M., Amorós, A., Tardón, A. et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J. Clin. Oncol. 24, 3664–3671 (2006).
d’Avis, P. Y., Robertson, S. C., Meyer, A. N., Bardwell, W. M., Webster, M. K. & Donoghue, D. J. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. Cell Growth Differ. 9, 71–78 (1998).
Rosty, C., Aubriot, M. H., Cappellen, D., Bourdin, J., Cartier, I., Thiery, J. P. et al. Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. Mol. Cancer 4, 15 (2005).
JGt, Taylor, Cheuk, A. T., Tsang, P. S., Chung, J. Y., Song, Y. K., Desai, K. et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J. Clin. Invest. 119, 3395–3407 (2009).
Tang, S., Hao, Y., Yuan, Y., Liu, R. & Chen, Q. Role of fibroblast growth factor receptor 4 in cancer. Cancer Sci. 109, 3024–3031 (2018).
Ruhe, J. E., Streit, S., Hart, S., Wong, C. H., Specht, K., Knyazev, P. et al. Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res. 67, 11368–11376 (2007).
Roidl, A., Foo, P., Wong, W., Mann, C., Bechtold, S., Berger, H. J., Streit, S., Ruhe, J. E., Hart, S., Ullrich, A. & Ho, H. K. The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells. Oncogene 29, 1543–1552 (2010).
Katoh, M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int. J. Mol. Med. 38, 3–15 (2016).
Mitelman, F., Johansson, B. & Mertens, F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 7, 233–245 (2007).
Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 21, 271–282 (2020).
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D. et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med. 378, 731–739 (2018).
Gettinger, S. N., Bazhenova, L. A., Langer, C. J., Salgia, R., Gold, K. A., Rosell, R. et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 17, 1683–1696 (2016).
O’Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994–1004 (2003).
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D. W. et al. Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377, 829–838 (2017).
Wu, Y. M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X. et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 3, 636–647 (2013).
Singh, D., Chan, J. M., Zoppoli, P., Niola, F., Sullivan, R., Castano, A. et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337, 1231–1235 (2012).
Katoh, M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat. Rev. Clin. Oncol. 16, 105–122 (2019).
Ray, M. E., Yang, Z. Q., Albertson, D., Kleer, C. G., Washburn, J. G., Macoska, J. A. & Ethier, S. P. Genomic and expression analysis of the 8p11–12 amplicon in human breast cancer cell lines. Cancer Res. 64, 40–47 (2004).
Paik, P. K. & Rudin, C. M. Missing the mark in FGFR1-amplified squamous cell cancer of the lung. Cancer 122, 2938–2940 (2016).
Ng, T. L., Yu, H., Smith, D. E., Boyle, T. A., York, E. R., Leedy, S. et al. Preselection of lung cancer cases using FGFR1 mRNA and gene copy number for treatment with ponatinib. Clin. Lung Cancer 20, e39–e51 (2019).
Chesi, M., Nardini, E., Brents, L. A., Schrock, E., Ried, T., Kuehl, W. M. & Bergsagel, P. L. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. 16, 260–264 (1997).
Richelda, R., Ronchetti, D., Baldini, L., Cro, L., Viggiano, L., Marzella, R. et al. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 90, 4062–4070 (1997).
Benayed, R., Offin, M., Mullaney, K., Sukhadia, P., Rios, K., Desmeules, P. et al. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden. Clin. Cancer Res. 25, 4712–4722 (2019).
Maher, C. A., Kumar-Sinha, C., Cao, X., Kalyana-Sundaram, S., Han, B., Jing, X. et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 458, 97–101 (2009).
Reeser, J. W., Martin, D., Miya, J., Kautto, E. A., Lyon, E., Zhu, E. et al. Validation of a targeted RNA sequencing assay for kinase fusion detection in solid tumors. J. Mol. Diagn. 19, 682–696 (2017).
Zheng, Z., Liebers, M., Zhelyazkova, B., Cao, Y., Panditi, D., Lynch, K. D. et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat. Med. 20, 1479–1484 (2014).
Childress, M. A., Himmelberg, S. M., Chen, H., Deng, W., Davies, M. A. & Lovly, C. M. ALK fusion partners impact response to ALK inhibition: differential effects on sensitivity, cellular phenotypes, and biochemical properties. Mol. Cancer Res. 16, 1724 (2018).
Mouliere, F., Chandrananda, D., Piskorz, A. M., Moore, E. K., Morris, J., Ahlborn, L. B. et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci. Transl. Med. 10, aat4921 (2018).
Moss, T. J., Ahnert, J. R., Oakley, H. D., Kahle, M., Karp, D. D., Pant, S. et al. Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120. J. Clin. Oncol. 37, 3056 (2019).
Varghese, A. M., Patel, J. A. A., Janjigian, Y. Y., Meng, F., Selcuklu, S. D., Zimel, C. et al. Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations. J. Clin. Oncol. 37, 4096 (2019).
Sharma, M., Schilero, C., Peereboom, D. M., Hobbs, B. P., Elson, P., Stevens, G. H. J. et al. Phase II study of Dovitinib in recurrent glioblastoma. J. Neurooncol. 144, 359–368 (2019).
Gainor, J. F. & Chabner, B. A. Ponatinib: accelerated disapproval. Oncologist 20, 847–848 (2015).
Hibi, M., Kaneda, H., Tanizaki, J., Sakai, K., Togashi, Y., Terashima, M. et al. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. Cancer Sci. 107, 1667–1676 (2016).
Cha, Y., Kim, H.-P., Lim, Y., Han, S.-W., Song, S.-H. & Kim, T.-Y. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro. Mol. Oncol. 12, 993–1003 (2018).
Mazzaferro, V., El-Rayes, B. F., Droz dit Busset, M., Cotsoglou, C., Harris, W. P., Damjanov, N. et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br. J. Cancer 120, 165–171 (2019).
Thompson, P. A., Young, N. P., Stumpf, C. R., Eam, B., Goel, V. K., Chen, J. et al. Abstract B133: eFT226, a first in class inhibitor of eIF4A1, targets FGFR1/2 and HER2 driven cancers. Mol. Cancer Ther. 18, B133–B133 (2019).
Sun, Y., Niu, W., Du, F., Du, C., Li, S., Wang, J., Li, L., Wang, F., Hao, Y., Li, C. & Chi, Y. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J. Hematol. Oncol. 9, 105 (2016).
Wang, Y., Bao, H., Zhang, N., Wang, F., He, Y. & Wu, T. Preclinical evaluation of MAX-40279, a FLT3/FGFR dual kinase inhibitor for treatment of acute myeloid leukemia. Blood 132, 3997 (2018).
Kim, S. T., Jang, H. L., Lee, S. J., Lee, J., Choi, Y. L., Kim, K. M. et al. Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification. Mol. Cancer Ther. 13, 2527–2536 (2014).
Holmström, T. H., Moilanen, A.-M., Ikonen, T., Björkman, M. L., Linnanen, T., Wohlfahrt, G. et al. ODM-203, a selective inhibitor of FGFR and VEGFR, shows strong antitumor activity, and induces antitumor immunity. Mol. Cancer Ther. 18, 28–38 (2019).
Boisseau, W., Euskirchen, P., Mokhtari, K., Dehais, C., Touat, M., Hoang-Xuan, K. et al. Molecular profiling reclassifies adult astroblastoma into known and clinically distinct tumor entities with frequent mitogen-activated protein kinase pathway alterations. Oncologist 24, 1584–1592 (2019).
Wu, D., Guo, M., Philips, M. A., Qu, L., Jiang, L., Li, J. et al. Crystal structure of the FGFR4/LY2874455 complex reveals insights into the Pan-FGFR selectivity of LY2874455. PLoS ONE 11, e0162491 (2016).
Perera, T. P. S., Jovcheva, E., Mevellec, L., Vialard, J., De Lange, D., Verhulst, T. et al. Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol. Cancer Ther. 16, 1010–1020 (2017).
Tsimafeyeu, I., Ludes-Meyers, J., Stepanova, E., Daeyaert, F., Khochenkov, D., Joose, J.-B. et al. Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models. Eur. J. Cancer 61, 20–28 (2016).
Fumarola, C., Bozza, N., Castelli, R., Ferlenghi, F., Marseglia, G., Lodola, A. et al. Expanding the arsenal of FGFR inhibitors: a novel chloroacetamide derivative as a new irreversible agent with anti-proliferative activity against FGFR1-amplified lung cancer cell lines. Front. Oncol. 9, 179 (2019).
Kalyukina, M., Yosaatmadja, Y., Middleditch, M. J., Patterson, A. V., Smaill, J. B. & Squire, C. J. TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure. ChemMedChem 14, 494–500 (2019).
Dai, S., Zhou, Z., Chen, Z., Xu, G. & Chen, Y. Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors. Cells. 8, 614 (2019).
Bai, A., Meetze, K., Vo, N. Y., Kollipara, S., Mazsa, E. K., Winston, W. M. et al. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res. 70, 7630–7639 (2010).
Sommer, A., Kopitz, C., Schatz, C. A., Nising, C. F., Mahlert, C., Lerchen, H. G. et al. Preclinical efficacy of the auristatin-based antibody-drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors. Cancer Res. 76, 6331–6339 (2016).
Kim, S. B., Meric-Bernstam, F., Kalyan, A., Babich, A., Liu, R., Tanigawa, T. et al. First-in-human phase I study of aprutumab ixadotin, a fibroblast growth factor receptor 2 antibody-drug conjugate (BAY 1187982) in patients with advanced cancer. Target Oncol. 14, 591–601 (2019).
Catenacci, D. V., Tesfaye, A., Tejani, M., Cheung, E., Eisenberg, P., Scott, A. J. et al. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Fut. Oncol. 15, 2073–2082 (2019).
Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P. et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J. Clin. Invest. 119, 1216–1229 (2009).
Trudel, S., Bergsagel, P. L., Singhal, S., Niesvizky, R., Comenzo, R. L., Bensinger, W. I. et al. A phase I study of the safety and pharmacokinetics of escalating doses of MFGR1877S, a fibroblast growth factor receptor 3 (FGFR3) antibody, in patients with relapsed or refractory t(4;14)-positive multiple myeloma. Blood 120, 4029 (2012).
Odonnell, P., Goldman, J. W., Gordon, M. S., Shih, K., Choi, Y. J., Lu, D. et al. A phase I dose-escalation study of MFGR1877S, a human monoclonal anti-fibroblast growth factor receptor 3 (FGFR3) antibody, in patients (pts) with advanced solid tumors. Eur. J. Cancer 48, 191–192 (2012).
Moek, K. L., de Groot, D. J. A., de Vries, E. G. E. & Fehrmann, R. S. N. The antibody-drug conjugate target landscape across a broad range of tumour types. Ann. Oncol. 28, 3083–3091 (2017).
Surguladze, D., Pennello, A., Ren, X., Mack, T., Rigby, A., Balderes, P. et al. LY3076226, a novel anti-FGFR3 antibody drug conjugate exhibits potent and durable anti-tumor activity in tumor models harboring FGFR3 mutations or fusions. Cancer Res. 79, 4835 (2019).
Bellmunt, J., Picus, J., Kohli, M., Arriaga, Y. E., Milowsky, M. I., Currie, G. et al. FIERCE-21: phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC). J. Clin. Oncol. 36, 4534 (2018).
Siefker-Radtke, A. O., Currie, G., Abella, E., Vaena, D. A., Kalebasty, A. R., Curigliano, G. et al. FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis. J. Clin. Oncol. 37, 4511 (2019).
Harding, T. C., Long, L., Palencia, S., Zhang, H., Sadra, A., Hestir, K. et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci. Transl. Med. 5, 178ra39 (2013).
Tolcher, A. W., Papadopoulos, K. P., Patnaik, A., Wilson, K., Thayer, S., Zanghi, J. et al. A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors. Ann. Oncol. 27, 526–532 (2016).
Morgensztern, D., Karaseva, N., Felip, E., Delgado, I., Burdaeva, O., Domine, M. et al. An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. Lung Cancer 136, 74–79 (2019).
van Brummelen, E. M. J., Levchenko, E., Domine, M., Fennell, D. A., Kindler, H. L., Viteri, S. et al. A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. Investig. New Drugs 38, 457–467 (2020).
Pal, S. K., Rosenberg, J. E., Hoffman-Censits, J. H., Berger, R., Quinn, D. I., Galsky, M. D. et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov. 8, 812–821 (2018).
Necchi, A., Pouessel, D., Leibowitz-Amit, R., Flechon, A., Gupta, S., Barthelemy, P. et al. Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA). Ann. Oncol. 29(suppl 8), VIII319–VIII320 (2018).
Schuler, M., Cho, B. C., Sayehli, C. M., Navarro, A., Soo, R. A., Richly, H. et al. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 20, 1454–1466 (2019).
Javle, M., Kelley, R. K., Roychowdhury, S., Weiss, K. H., Abou-Alfa, G. K., Macarulla, T. et al. Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions. Ann. Oncol. 29(suppl 8), VIII720 (2018).
Vogel, A. (ed.). FIGHT-202: a phase II study of pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma. ESMO 2019 Congress; 2019; Barcelona, Spain. Ann. Oncol. 30(Suppl_5), v851–v934 (2019).
Bahleda, R., Italiano, A., Hierro, C., Mita, A., Cervantes, A., Chan, N. et al. Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin. Cancer Res. 25, 4888–4897 (2019).
Park, J. O., Feng, Y.-H., Chen, Y.-Y., Su, W.-C., Oh, D.-Y., Shen, L. et al. Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations. J. Clin. Oncol. 37, 4117 (2019).
Goyal, L., Shi, L., Liu, L. Y., Fece de la Cruz, F., Lennerz, J. K., Raghavan, S. et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 9, 1064–1079 (2019).
Meric-Bernstam, F., Arkenau, H., Tran, B., Bahleda, R., Kelley, R., Hierro, C. et al. Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors. Ann. Oncol. 29(Suppl_5), O–001 (2018).
Tao, J. J., Schram, A. M. & Hyman, D. M. Basket studies: redefining clinical trials in the era of genome-driven oncology. Annu. Rev. Med. 69, 319–331 (2018).
Yanochko, G. M., Vitsky, A., Heyen, J. R., Hirakawa, B., Lam, J. L., May, J. et al. Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunction. Toxicol. Sci. 135, 451–464 (2013).
Betrian, S., Gomez-Roca, C., Vigarios, E., Delord, J. P. & Sibaud, V. Severe onycholysis and eyelash trichomegaly following use of new selective pan-FGFR inhibitors. JAMA Dermatol. 153, 723–725 (2017).
Carr, D. R., Pootrakul, L., Chen, H. Z. & Chung, C. G. Metastatic calcinosis cutis associated with a selective FGFR inhibitor. JAMA Dermatol. 155, 122–123 (2019).
Kim, R. D., Sarker, D., Meyer, T., Yau, T., Macarulla, T., Park, J. W. et al. First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov. 9, 1696–1707 (2019).
Goyal, L., Saha, S. K., Liu, L. Y., Siravegna, G., Leshchiner, I., Ahronian, L. G. et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 7, 252–263 (2017).
Krook, M. A., Lenyo, A., Wilberding, M., Barker, H., Dantuono, M., Bailey, K. M. et al. Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. Mol. Cancer Ther. 19, 847–857 (2020).
Krook, M. A., Bonneville, R., Chen, H. Z., Reeser, J. W., Wing, M. R., Martin, D. M. et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb. Mol. Case Stud. 5, a004002 (2019).
Patani, H., Bunney, T. D., Thiyagarajan, N., Norman, R. A., Ogg, D., Breed, J. et al. Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use. Oncotarget 7, 24252–24268 (2016).
Byron, S. A., Chen, H., Wortmann, A., Loch, D., Gartside, M. G., Dehkhoda, F. et al. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia 15, 975–988 (2013).
Hahn, N. M., Bivalacqua, T. J., Ross, A. E., Netto, G. J., Baras, A., Park, J. C. et al. A phase II trial of dovitinib in BCG-unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. Clin. Cancer Res. 23, 3003–3011 (2017).
Malchers, F., Ercanoglu, M., Schutte, D., Castiglione, R., Tischler, V., Michels, S. et al. Mechanisms of primary drug resistance in FGFR1-amplified lung cancer. Clin. Cancer Res. 23, 5527–5536 (2017).
Chen, J., Bell, J., Lau, B. T., Whittaker, T., Stapleton, D. & Ji, H. P. A functional CRISPR/Cas9 screen identifies kinases that modulate FGFR inhibitor response in gastric cancer. Oncogenesis 8, 33 (2019).
Cowell, J. K., Qin, H., Hu, T., Wu, Q., Bhole, A. & Ren, M. Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas. Int. J. Cancer 141, 1822–1829 (2017).
Chang, J., Wang, S., Zhang, Z., Liu, X., Wu, Z., Geng, R. et al. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. Oncotarget 6, 2009–2022 (2015).
Hanker, A. B., Garrett, J. T., Estrada, M. V., Moore, P. D., Ericsson, P. G., Koch, J. P. et al. HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2. Clin. Cancer Res. 23, 4323–4334 (2017).